Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07439653 · ClinicalTrials.gov registry record · Phase 1
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1 study, sponsored by TORL Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
NCT07439653: Recruiting Phase 1 study, sponsored by TORL Biotherapeutics.
NCT07439653 is a Phase 1 study that is actively recruiting participants, run by TORL Biotherapeutics. The registered enrollment target is 155 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (158% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07439653, a Phase 1 study, is actively recruiting participants, sponsored by TORL Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
Study Summary
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Primary Outcome
Assessment of adverse events according to NCI-CTCAE Version 5.0
Interventions
- DRUG TORL-5-700
- DRUG TORL-5-700 at MTD/RP2D
- DRUG TORL-5-700 at MTD/RP2D in combination with another agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 1 |
What NCT07439653 shows while recruiting
NCT07439653 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (158% higher).
The record links to 0 conditions, and to 3 interventions - of which TORL-5-700 is the first listed.
NCT07439653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07439653 about?
NCT07439653 is a clinical study titled "A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma". A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
What is the current status of trial NCT07439653?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2026-03-31. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT07439653?
The interventions under investigation include: TORL-5-700 (DRUG), TORL-5-700 at MTD/RP2D (DRUG), TORL-5-700 at MTD/RP2D in combination with another agent (DRUG).
Who is sponsoring clinical trial NCT07439653?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07439653's enrollment target sits among peer trials
155 352nd of 2000 higher than 1,645 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI